Thema: US34960Q3074
FBIO, US34960Q3074
charts-6531107_1920.jpg - Foto: THN
Fortress Biotech stock: Subsidiary licenses FB-607 from Cedars-Sinai
Fortress Biotech stock drew attention after a subsidiary licensed FB-607 from Cedars-Sinai for irritable bowel syndrome with diarrhea. The Phase 2 study is ongoing.
ad-hoc-news.de, heute 03:01 Uhr
FBIO, US34960Q3074
Fortress Biotech repaid USD 15.00 million debt. Fortress ...
Fortress Biotech repaid USD 15.00 million under Oaktree on September 30, 2026. Fortress Biotech stock was last at USD 1.94 on October 20, 2026.
ad-hoc-news.de, 21.10.26 02:00 Uhr
FBIO, US34960Q3074
Fortress Biotech repays USD 15 million debt: what it means ...
Fortress Biotech repaid USD 15.00 million of debt on September 30, 2026. Fortress Biotech stock sits at a USD 64.8 million market value.
ad-hoc-news.de, 14.10.26 06:32 Uhr
FBIO, US34960Q3074
FBIO stock falls 1.91 percent as debt is repaid
FBIO stock traded at USD 2.05 on October 6, 2026, after Fortress settled USD 15.0 million of debt. Q2 revenue reached USD 18.7 million.
ad-hoc-news.de, 07.10.26 05:20 Uhr
FBIO, US34960Q3074
Fortress Biotech stock gains as USD 15.0 million debt is ...
Fortress Biotech stock carries USD 15.0 million less Oaktree principal after September 30, 2026. Second-quarter revenue rose 14 percent to USD 18.7 million.
ad-hoc-news.de, 05.10.26 17:12 Uhr
FBIO, US34960Q3074
Fortress Biotech stock fell 1.93 percent on October 2
